miR-34a is essential for p19Arf-driven cell cycle arrest

Cell Cycle

Volumn 13, Issue 5, 2014, Pages 792-800

  Iqbal, Nida ^a   Mei, Jie ^a,b   Liu, Jing ^a   Skapek, Stephen X ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^c CHILDREN S MEDICAL CENTER   (United States)

Author keywords

Cell cycle; miR 34a; p53; Pdgfr ; Tumor suppression; Vascular remodeling

Indexed keywords

MICRORNA 34A; P19 ARF PROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN; PROTEIN P53; RNA ANTIBODY; UNCLASSIFIED DRUG; CDKN2A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MICRORNA; MIRN34 MICRORNA, MOUSE;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL CELL CULTURE; ARF GENE; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; EMBRYO; EYE DEVELOPMENT; FIBROBLAST; GENE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; MOUSE EMBRYO; MOUSE MODEL; NONHUMAN; PLASMID; PREDICTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REPORTER GENE; RNA SEQUENCE; WILD TYPE; 129 MOUSE; ANIMAL; C57BL MOUSE; CELL CYCLE CHECKPOINT; CELL LINE; EMBRYOLOGY; EYE; GENETICS; METABOLISM;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EYE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICRORNAS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897974271     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27725     Document Type: Article

References (48)

1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-30; PMID:7736585; http://dx.doi.org/10.1016/0092-8674(95)90385-2
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31; PMID:9039259; http://dx.doi.org/10.1016/S0092-8674(00)81871-1
3. rd, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436-40; PMID:8153634; http://dx.doi.org/10.1126/science.8153634
4. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83:993-1000; PMID:8521522; http://dx.doi.org/10.1016/0092-8674(95)90214-7
5. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92:713-23; PMID:9529248; http://dx.doi.org/10.1016/S0092- 8674(00)81400-2
6. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34; PMID:9529249; http://dx.doi.org/10. 1016/S0092-8674(00)81401-4
7. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 1998; 95:8292-7; PMID:9653180; http://dx.doi.org/10.1073/ pnas.95.14.8292
8. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10:1054-72; PMID:8654922; http://dx.doi.org/10.1101/gad.10.9.1054
9. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000; 14:2358-65; PMID:10995391; http://dx.doi.org/10.1101/gad.827300
10. Sugimoto M, Kuo ML, Roussel MF, Sherr CJ. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 2003; 11:415-24; PMID:12620229; http://dx.doi.org/10.1016/S1097-2765(03)00057-1
11. Eymin B, Karayan L, Séité P, Brambilla C, Brambilla E, Larsen CJ, Gazzéri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001; 20:1033-41; PMID:11314038; http://dx.doi.org/10.1038/sj.onc.1204220
12. Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 2004; 431:712-7; PMID:15361884; http://dx.doi.org/10.1038/nature02958
13. Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, Mori Y, Raychaudhuri P. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem 2004; 279:36698-707; PMID:15199070; http://dx.doi.org/10.1074/jbc.M312305200
14. Rocha S, Campbell KJ, Perkins ND. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol Cell 2003; 12:15-25; PMID:12887889; http://dx.doi.org/10.1016/S1097-2765(03)00223-5
15. Silva RL, Thornton JD, Martin AC, Rehg JE, Bertwistle D, Zindy F, Skapek SX. Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye. EMBO J 2005; 24:2803-14; PMID:16037818; http://dx.doi.org/10.1038/sj.emboj.7600751
16. Rizos H, Woodruff S, Kefford RF. p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. Cell Cycle 2005; 4:597-603; PMID:15876874; http://dx.doi.org/10.4161/ cc.4.4.1588
17. Tago K, Chiocca S, Sherr CJ. Sumoylation induced by the Arf tumor suppressor: a p53-independent function. Proc Natl Acad Sci U S A 2005; 102:7689-94; PMID:15897463; http://dx.doi.org/10.1073/pnas.0502978102
18. Kuchenreuther MJ, Weber JD. The ARF tumor-suppressor controls Drosha translation to prevent Ras-driven transformation. Oncogene 2013; PMID:23318441; http://dx.doi.org/10.1038/onc.2012.601
19. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res 1999; 59:2217-22; PMID:10232611
20. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4:1-7; PMID:7922305; http://dx.doi.org/10.1016/S0960-9822(00)00002-6
21. Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol 2004; 2:E242; PMID:15314658; http://dx.doi.org/10.1371/journal.pbio.0020242
22. Ulanet DB, Hanahan D. Loss of p19(Arf) facilitates the angiogenic switch and tumor initiation in a multistage cancer model via p53-dependent and independent mechanisms. PLoS One 2010; 5:e12454; PMID:20805995; http://dx.doi.org/10.1371/journal.pone.0012454
23. McKeller RN, Fowler JL, Cunningham JJ, Warner N, Smeyne RJ, Zindy F, Skapek SX. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci U S A 2002; 99:3848-53; PMID:11891301; http://dx.doi.org/10.1073/pnas.052484199
24. Martin AC, Thornton JD, Liu J, Wang X, Zuo J, Jablonski MM, Chaum E, Zindy F, Skapek SX. Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene. Invest Ophthalmol Vis Sci 2004; 45:3387-96; PMID:15452040; http://dx.doi.org/10.1167/iovs.04-0349
25. Gromley A, Churchman ML, Zindy F, Sherr CJ. Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice. Proc Natl Acad Sci U S A 2009; 106:6285-90; PMID:19339492; http://dx.doi.org/10.1073/pnas.0902310106
26. Ikeda S, Hawes NL, Chang B, Avery CS, Smith RS, Nishina PM. Severe ocular abnormalities in C57BL/6 but not in 129/Sv p53-deficient mice. Invest Ophthalmol Vis Sci 1999; 40:1874-8; PMID:10393064
27. Thornton JD, Swanson DJ, Mary MN, Pei D, Martin AC, Pounds S, Goldowitz D, Skapek SX. Persistent hyperplastic primary vitreous due to somatic mosaic deletion of the arf tumor suppressor. Invest Ophthalmol Vis Sci 2007; 48:491-9; PMID:17251441; http://dx.doi.org/10.1167/iovs.06-0765
28. Widau RC, Zheng Y, Sung CY, Zelivianskaia A, Roach LE, Bachmeyer KM, Abramova T, Desgardin A, Rosner A, Cunningham JM, et al. p19Arf represses platelet-derived growth factor receptor β by transcriptional and posttranscriptional mechanisms. Mol Cell Biol 2012; 32:4270-82; PMID:22907756; http://dx.doi.org/10.1128/MCB.06424-11
29. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005; 37:766-70; PMID:15965474; http://dx.doi.org/10.1038/ng1590
30. Ambros V, Lee RC, Lavanway A, Williams PT, Jewell D. MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr Biol 2003; 13:807-18; PMID:12747828; http://dx.doi.org/10.1016/S0960-9822(03)00287-2
31. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294:853-8; PMID:11679670; http://dx.doi.org/10.1126/science.1064921
32. Li C, Finkelstein D, Sherr CJ. Arf tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells. Proc Natl Acad Sci U S A 2013; 110:E1112-21; PMID:23487795; http://dx.doi.org/10.1073/pnas.1302184110
33. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26:745-52; PMID:17540599; http://dx.doi.org/10.1016/j.molcel.2007.05. 010
34. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6:1586-93; PMID:17554199; http://dx.doi.org/10. 4161/cc.6.13.4436
35. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26:731-43; PMID:17540598; http://dx.doi.org/10.1016/j.molcel.2007.05.017
36. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447:1130-4; PMID:17554337; http://dx.doi.org/10.1038/ nature05939
37. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17:1298-307; PMID:17656095; http://dx.doi.org/10.1016/j.cub.2007.06.068
38. Karali M, Peluso I, Gennarino VA, Bilio M, Verde R, Lago G, Dollé P, Banfi S. miRNeye: a microRNA expression atlas of the mouse eye. BMC Genomics 2010; 11:715; PMID:21171988; http://dx.doi.org/10.1186/1471-2164-11-715
39. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26:5017-22; PMID:17297439; http://dx.doi.org/10.1038/sj.onc.1210293
40. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17:193-9; PMID:19461653; http://dx.doi.org/10.1038/cdd.2009.56
41. Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, Sherr CJ. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A 2003; 100:15930-5; PMID:14665695; http://dx.doi.org/10.1073/pnas.2536808100
42. Freeman-Anderson NE, Zheng Y, McCalla-Martin AC, Treanor LM, Zhao YD, Garfin PM, He TC, Mary MN, Thornton JD, Anderson C, et al. Expression of the Arf tumor suppressor gene is controlled by Tgfbeta2 during development. Development 2009; 136:2081-9; PMID:19465598; http://dx.doi.org/10.1242/dev.033548
43. Reichel MB, Ali RR, D'Esposito F, Clarke AR, Luthert PJ, Bhattacharya SS, Hunt DM. High frequency of persistent hyperplastic primary vitreous and cataracts in p53-deficient mice. Cell Death Differ 1998; 5:156-62; PMID:10200460; http://dx.doi.org/10.1038/sj.cdd.4400326
44. Concepcion CP, Han YC, Mu P, Bonetti C, Yao E, D'Andrea A, Vidigal JA, Maughan WP, Ogrodowski P, Ventura A. Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet 2012; 8:e1002797; PMID:22844244; http://dx.doi.org/10.1371/journal.pgen.1002797
45. Gibson SL, Dai CY, Lee HW, DePinho RA, Gee MS, Lee WMF, Furth EE, Brensinger C, Enders GH. Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. Cancer Res 2003; 63:742-6; PMID:12591718
46. Kawagishi H, Nakamura H, Maruyama M, Mizutani S, Sugimoto K, Takagi M, Sugimoto M. ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA. Cancer Res 2010; 70:4749-58; PMID:20501856; http://dx.doi.org/10. 1158/0008-5472.CAN-10-0368
47. Sage J, Miller AL, Pérez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003; 424:223-8; PMID:12853964; http://dx.doi.org/10.1038/nature01764
48. Mei J, Bachoo R, Zhang CL. MicroRNA-146a inhibits glioma development by targeting Notch1. Mol Cell Biol 2011; 31:3584-92; PMID:21730286; http://dx.doi.org/10.1128/MCB.05821-11